No black box warning on record for Candesartan Cilexetil And Hydrochlorothiazide

As of the latest FDA labeling reviewed, Candesartan Cilexetil And Hydrochlorothiazide (CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Candesartan Cilexetil And Hydrochlorothiazide medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal f

No black box warning on record for Candesartan Cilexetil And Hydrochlorothiazide

Other warnings & precautions

WARNINGS Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal f

Candesartan Cilexetil And Hydrochlorothiazide Black Box Warning

No black box warning on record for Candesartan Cilexetil And Hydrochlorothiazide

Other warnings & precautions

Candesartan Cilexetil And Hydrochlorothiazide Black Box Warning

No black box warning on record for Candesartan Cilexetil And Hydrochlorothiazide

Other warnings & precautions